brilliant Blue G 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
5359 6104-58-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • brilliant blue G
  • tissueblue
Brilliant Blue G has been shown to selectively stain the ILM, but not the epiretinal membrane nor the retina, making it easier to visualize the membrane for removal, although the exact mechanism of this selectivity has not been elucidated.
  • Molecular weight: 831.04
  • Formula: C47H48N3O7S2
  • CLOGP: 0.48
  • LIPINSKI: 1
  • HAC: 10
  • HDO: 1
  • TPSA: 141.91
  • ALOGS: -7.42
  • ROTB: 15
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,FGFR1,FLT3,GRK2,GRK3,GSK3B,IGF1R,IKBKB,INSR,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K1,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K21,MAP3K7,MAP3K8,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SGK1,SIK2,SIK3,SRC,STK10,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 93
kinase-selectivity-class AXL,BRAF,DDR1,EIF2AK3,EPHB4,ERBB2,GRK2,MAP2K6,MAPK7,PDK4,SIK2,STK33,TEK,ZAP70 14
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 20, 2019 FDA DUTCH OPHTHALMIC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175533 Dyes
FDA EPC N0000194020 Disclosing Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Staining method indication 127790008




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.61 Basic
pKa2 7.01 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
0.025% TISSUEBLUE DUTCH OPHTHALMIC N209569 Dec. 20, 2019 RX SOLUTION OPHTHALMIC Dec. 20, 2026 INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
P2X purinoceptor 7 Ion channel ANTAGONIST IC50 8 IUPHAR
Alpha-synuclein Transporter IC50 5.27 CHEMBL
P2X purinoceptor 7 Ion channel IC50 6.96 CHEMBL

External reference:

IDSource
4039525 VANDF
CHEBI:756625 CHEBI
CHEMBL4173394 ChEMBL_ID
D10799 KEGG_DRUG
4147 IUPHAR_LIGAND_ID
DB15594 DRUGBANK_ID
C0056270 UMLSCUI
333643 MMSL
38372 MMSL
61363 PUBCHEM_CID
014584 NDDF
M1ZRX790SI UNII
1998867 RXNORM
M1ZRX790SI INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TISSUEBLUE HUMAN PRESCRIPTION DRUG LABEL 1 68803-722 INJECTION, SOLUTION 0.01 mg INTRAOCULAR NDA 19 sections